JP6437467B2 - 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 - Google Patents

線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 Download PDF

Info

Publication number
JP6437467B2
JP6437467B2 JP2015562041A JP2015562041A JP6437467B2 JP 6437467 B2 JP6437467 B2 JP 6437467B2 JP 2015562041 A JP2015562041 A JP 2015562041A JP 2015562041 A JP2015562041 A JP 2015562041A JP 6437467 B2 JP6437467 B2 JP 6437467B2
Authority
JP
Japan
Prior art keywords
macrophages
polypeptide
differentiation
fibrosis
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015562041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521114A5 (enExample
JP2016521114A (ja
Inventor
アントニウス ジョゼフ ジャンセン リチャード
アントニウス ジョゼフ ジャンセン リチャード
ニコレテ レケルケルケル アンマリ
ニコレテ レケルケルケル アンマリ
バン エス トーマス
バン エス トーマス
メルチオル ペトルス スタレン ジョハネス
メルチオル ペトルス スタレン ジョハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2016521114A publication Critical patent/JP2016521114A/ja
Publication of JP2016521114A5 publication Critical patent/JP2016521114A5/ja
Application granted granted Critical
Publication of JP6437467B2 publication Critical patent/JP6437467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2015562041A 2013-03-14 2014-03-07 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 Active JP6437467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781220P 2013-03-14 2013-03-14
US61/781,220 2013-03-14
PCT/EP2014/054441 WO2014139883A1 (en) 2013-03-14 2014-03-07 Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2016521114A JP2016521114A (ja) 2016-07-21
JP2016521114A5 JP2016521114A5 (enExample) 2017-04-06
JP6437467B2 true JP6437467B2 (ja) 2018-12-19

Family

ID=50239627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562041A Active JP6437467B2 (ja) 2013-03-14 2014-03-07 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法

Country Status (4)

Country Link
US (2) US20160054304A1 (enExample)
EP (1) EP2972322B1 (enExample)
JP (1) JP6437467B2 (enExample)
WO (1) WO2014139883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149978A1 (en) * 2017-02-16 2018-08-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS
US11536723B2 (en) 2017-05-24 2022-12-27 Mayo Foundation For Medical Education And Research Integrated immunoassay
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
CA3110618A1 (en) * 2018-08-29 2020-03-05 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
GB201900724D0 (en) * 2019-01-18 2019-03-06 King S College London Antibody
IL284066B2 (en) * 2019-08-01 2025-06-01 Illumina Inc Flow cells
CN114269945B (zh) 2019-08-23 2024-07-19 宝洁公司 鉴定纤维化过程的调节物的方法
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition
WO2022060466A1 (en) * 2020-09-21 2022-03-24 Massachusetts Institute Of Technology Compounds, targets and pathways for macrophage modulation
CN117959323B (zh) * 2024-01-12 2025-01-21 南方医科大学南方医院 环状rna在制备防治放射性肝纤维化的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
GB9620749D0 (en) 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US6004753A (en) * 1997-12-01 1999-12-21 Incyte Pharmaceuticals, Inc. Human S1-5 ECMP-like protein
GB2335035B (en) 1998-03-03 2003-05-28 Brax Genomics Ltd Screening for functional antisense agents
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
JP2004123539A (ja) * 2001-03-13 2004-04-22 Japan Tobacco Inc 新規ピラゾロピリジン化合物及び医薬用途
JP2004123537A (ja) * 2000-06-20 2004-04-22 Japan Tobacco Inc ピラゾロピリジン化合物及びその医薬用途
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
JP2005300158A (ja) * 2001-03-26 2005-10-27 Nippon Shinyaku Co Ltd 増殖性糸球体腎炎の予防・治療用薬物のスクリーニング方法
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2003301991A1 (en) * 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
JPWO2011087051A1 (ja) * 2010-01-14 2013-05-20 国立大学法人金沢大学 Ｓ１ｐ２受容体アンタゴニストを含む粥状動脈硬化治療薬
KR20130005086A (ko) * 2011-07-05 2013-01-15 한국과학기술연구원 대장암 진단용 단백질 마커 피불린-4 및 이에 대한 항체를 포함하는 대장암 진단 키트

Also Published As

Publication number Publication date
EP2972322A1 (en) 2016-01-20
WO2014139883A1 (en) 2014-09-18
EP2972322B1 (en) 2019-03-06
US20180045713A1 (en) 2018-02-15
US20160054304A1 (en) 2016-02-25
JP2016521114A (ja) 2016-07-21
US10048250B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
JP6437467B2 (ja) 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
JP4879906B2 (ja) 関節変性疾患及び炎症性疾患の治療に有用な分子標的及び化合物、並びにそれらの同定方法
US20160003808A1 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
JP2011515653A (ja) 神経変性疾患の治療に有用な標的配列及びそれらの同定方法
JP2014110799A (ja) 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
JP2012517822A (ja) 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
Gaddam et al. The microRNA‐204‐5p inhibits APJ signalling and confers resistance to cardiac hypertrophy and dysfunction
US9952202B2 (en) Methods of identifying compounds for the treatment of fibrosis by using S1PR5
Hodgson et al. TDP-43 is a master regulator of paraspeckle condensation
JP2011517339A (ja) 神経変性疾患の治療に有用な分子標的及び化合物並びにこれらの同定方法
US8765376B2 (en) Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant cystic fibrosis transmembrane conductance regulator
WO2014082993A2 (en) Molecular targets and compounds, and methods to identify the same, useful in the down-regulation of the th2 response
JP6200929B2 (ja) 変形性関節症の治療のための方法及び手段
JP2012518181A (ja) 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
US20220251569A1 (en) Treatment and prevention of disease mediated by wwp2
US20110306655A1 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2024003205A1 (en) Long non-coding rnas as target for treating fibrosis and cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151207

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181114

R150 Certificate of patent or registration of utility model

Ref document number: 6437467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250